A Leptin Receptor Antagonist Attenuates Adipose Tissue Browning and Muscle Wasting in Infantile Nephropathic Cystinosis-Associated Cachexia

Mice lacking the functional cystinosin gene (Ctns(-/-)), a model of infantile nephropathic cystinosis (INC), exhibit the cachexia phenotype with adipose tissue browning and muscle wasting. Elevated leptin signaling is an important cause of chronic kidney disease-associated cachexia. The pegylated leptin receptor antagonist (PLA) binds to but does not activate the leptin receptor. We tested the efficacy of this PLA in Ctns(-/-) mice. We treated 12-month-old Ctns(-/-) mice and control mice with PLA (7 mg/kg/day, IP) or saline as a vehicle for 28 days. PLA normalized food intake and weight gain, increased fat and lean mass, decreased metabolic rate and improved muscle function. It also attenuated perturbations of energy homeostasis in adipose tissue and muscle in Ctns(-/-) mice. PLA attenuated adipose tissue browning in Ctns(-/-) mice. PLA increased gastrocnemius weight and fiber size as well as attenuated muscle fat infiltration in Ctns(-/-) mice. This was accompanied by correcting the increased expression of muscle wasting signaling while promoting the decreased expression of myogenesis in gastrocnemius of Ctns(-/-) mice. PLA attenuated aberrant expressed muscle genes that have been associated with muscle atrophy, increased energy expenditure and lipolysis in Ctns(-/-) mice. Leptin antagonism may represent a viable therapeutic strategy for adipose tissue browning and muscle wasting in INC.

Automated summary

The study demonstrates that the use of pegylated leptin receptor antagonist (PLA) can improve weight, muscle, and adipose tissue health in infantile nephropathic cystinosis (INC) mice, reduce metabolic rate, enhance muscle function, and decrease aberrant gene expression in adipose tissue and muscle.